Crizotinib (Standard)

CAT: 0804-HY-50878R-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-50878R-01Size:5 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Crizotinib (Standard) is the analytical standard of Crizotinib. This product is intended for research and analytical applications. Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive ALK and c-Met inhibitor with IC50s of 20 and 8 nM, respectively. Crizotinib inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC50s of 24 and 11 nM in cell-based assays, respectively. Crizotinib is also a ROS1 inhibitor. Crizotinib has effective tumor growth inhibition[1][2][3].
CAS Number
[877399-52-5]
Product Name Alternative
PF-02341066 (Standard)
UNSPSC
12352005
Target
Anaplastic lymphoma kinase (ALK) ; Autophagy; c-Met/HGFR; Reference Standards; ROS Kinase
Type
Reference Standards
Related Pathways
Autophagy; Others; Protein Tyrosine Kinase/RTK
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/crizotinib-standard.html
Smiles
ClC1=C(F)C=CC(Cl)=C1[C@H](OC2=CC(C3=CN(N=C3)C4CCNCC4)=CN=C2N)C
Molecular Formula
C21H22Cl2FN5O
Molecular Weight
450.34
References & Citations
[1]Zou HY, et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 2007, 67 (9), 4408-4417.|[2]Christensen JG, et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther. 2007, 6 (12 Pt 1), 3314-3322.|[3]Cui JJ, et al. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK) . J Med Chem. 2011 Sep 22;54 (18) :6342-63.|[4]Cullinane C, et al. Differential (18) F-FDG and 3'-deoxy-3'- (18) F-fluorothymidine PET responses to pharmacologic inhibition of the c-MET receptor in preclinical tumor models. J Nucl Med. 2011 Aug;52 (8) :1261-7|[5]Shen A, et al. c-Myc alterations confer therapeutic response and acquired resistance to c-Met inhibitors in MET-addicted cancers. Cancer Res. 2015 Nov 1;75 (21) :4548-59.|[6]Umapathy G, et al. The kinase ALK stimulates the kinase ERK5 to promote the expression of the oncogene MYCN in neuroblastoma. Sci Signal. 2014 Oct 28;7 (349) :ra102.|[7]Tucker ER, et al. Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on-target ALK inhibitors in neuroblastoma. Mol Oncol. 2017 Aug;11 (8) :996-1006.|[8]Liu H, et al. Identifying and Targeting Sporadic Oncogenic GeneticLiu H, et al. Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple Negative Breast Cancer. Cancer Discov. 2018 Mar;8 (3) :354-369.
Shipping Conditions
Room temperature
Scientific Category
Reference Standards

Related Products

CatalogName
HY-75468RCrizotinib impurity 1 (Standard)
HY-50878-01Crizotinib
HY-149696IR-Crizotinib
HY-50878S1Crizotinib-d8
HY-50878S2Crizotinib-d9
HY-100549-01(S) -Crizotinib
HY-50878A-01Crizotinib (hydrochloride)
HY-50878BCrizotinib (acetate)
HY-50878SCrizotinib-d5
HY-50878ASCrizotinib-d9 (hydrochloride)

Alternative Products

CatalogName
T1661-01Crizotinib
RM-C182606-01(S) -Crizotinib
T8399-01Crizotinib hydrochloride
MBS578906(S)-crizotinib
A3020-100(R)-Crizotinib
007107Crizotinib discontinued
T82049-01IR-Crizotinib
T1661L-01Crizotinib acetate

Popular Products